Sanofi gets expanded meningitis vaccine approval

Apr 25, 2011

(AP) -- Sanofi Pasteur, the vaccines division of Sanofi-Aventis, said Monday the Food and Drug Administration approved the company's bacterial meningitis vaccine Menactra for children between the ages of 9 months and 23 months.

The disease is fairly rare in the United States, but those who get it develop symptoms quickly and can die in only a few days. Survivors can suffer mental disabilities, hearing loss and paralysis. The is spread by coughing, sneezing and kissing, and most cases occur in previously healthy children and young adults.

The company said this is the first U.S. approval for a bacterial for the age group between 9 months and 23 months.

Menactra was already approved for people ages 11 through 55 and children between 2 and 10 years old.

Explore further: WHO: Millions of Ebola vaccine doses ready in 2015 (Update)

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA expands meningitis vaccine approval

Oct 22, 2007

The U.S. Food and Drug Administration has expanded approval for the use of Menactra, a bacterial meningitis vaccine, to children ages 2 to 10.

CDC panel: Teens need another meningitis shot

Oct 27, 2010

(AP) -- Teens should get a booster dose of the vaccine for bacterial meningitis because a single shot doesn't work as long as expected, a federal advisory panel said Wednesday.

ActHIB vaccine recalled in Japan

Mar 11, 2011

Sanofi Pasteur and Daiichi Sankyo on Friday announced a recall of the ActHIB vaccine in Japan after an "unidentified substance" was found in two syringes.

Recommended for you

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 0